Ascendis Pharma AS (MEX:ASNDN) Moat Score: 4/10 (As of Jun. 25, 2026)


MEX:ASNDN Ascendis Pharma AS MEX:ASNDN
37 GF Score
Price MXN3,851.44
! 1 Warning Sign
View Full Analysis

What is Ascendis Pharma AS Moat Score?

Ascendis Pharma AS MEX:ASNDN 37 Moat Score is 4 as of Jun. 25, 2026. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,405 Biotechnology companies, Ascendis Pharma AS ranks better than 88.83% on this metric.

Ascendis Pharma AS has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Ascendis Pharma AS has Narrow Moat: Ascendis Pharma AS has valuable intellectual property and strong R&D capabilities in the biotech sector. However, it faces significant competition and lacks strong brand strength, customer loyalty, and regulatory barriers, resulting in a modest moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Ascendis Pharma AS might have Narrow Moat - Discernible but modest moat.

Ascendis Pharma AS  (MEX:ASNDN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Ascendis Pharma AS Moat Score Related Terms

MEX:ASNDN vs SMMT, BBIO, JAZZ: Moat Score Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascendis Pharma AS Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Moat Score distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Moat Score falls into.


MEX:ASNDN
37GF Score
Ascendis Pharma AS MEX:ASNDN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Ascendis Pharma AS (MEX:ASNDN) has a Moat Score of 4 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Ascendis Pharma AS ranks #157 out of 1405 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Ascendis Pharma AS's Moat Score too high?
Ascendis Pharma AS's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Ascendis Pharma AS's value of 4 is 100% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #157 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Moat Score compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #157 out of 1405 companies for Moat Score. This places Ascendis Pharma AS in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Ascendis Pharma AS's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current Moat Score is 4 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges ASND:USA
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for MEX:ASNDN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,851.44
Price